HOME » About Us » Leadership Team » Board of Directors

    Board of Directors

    Dr. Raghunath A. Mashelkar, Chairman of the Board

    Dr. Raghunath Anant Mashelkar was the Director-General of the Council of Scientific and Industrial Research for over eleven years, and also served as the President of Indian National Science Academy.

    He is only the third Indian engineer to have been elected as Fellow of Royal Society (FRS), London in the twentieth century. He was elected Foreign Associate of the US National Academy of Science in 2005, Foreign Fellow of US National Academy of Engineering in 2003 and Fellow of Royal Academy of Engineering, UK in 1996. Dr. Mashelkar has won over 50 awards and medals from several bodies for his outstanding contribution in the field of science and technology. He has been awarded honorary doctorates by 27 universities from across the world. He is the only scientist so far to have won the JRD Tata Corporate Leadership Award. In 2011, Dr. Mashelkar was named National Research Professor by the Government of India.
     

    Venkateswarlu Nelabhotla (N. Venkat), Co-Founder & CEO

    Venkat comes with a very rich and global experience of successfully leading organizations in the Life sciences and Consumer Products businesses. He has held top management roles in the life sciences space in companies like Shantha Biotech (A Sanofi Company) and Aurobindo Pharma and he immensely contributed to their all-round growth. Shantha Biotech a biosimilar and vaccine company was eventually acquired by Sanofi for around $ 800 MN in 2010. He has been a part of significant revenue growth and significant value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas.

    He has held CEO roles in Emami and Cavinkare, CPG companies, growing them significantly with an all rounded approach. During his stint at Emami (a listed company) as CEO, the company's value went up by 4 times within 3 years. The momentum thus created, has made Emami a large market cap FMCG company in India now. During early part of his career, he created some very successful brands in Cavinkare, a leading CPG company from India, and built the organization with a 10X revenue increase in 6 years’ time and that early momentum has made Cavinkare one of the established Consumer product companies in India. He comes with core strengths in Strategy, Innovation, Marketing, Organization building, Finance, M&A and Governance. He has been an integral part of many industrial forums in Life sciences and CPG business.

    Contact Information: nvenkat@vyome.in

     

    Dr. Shiladitya Sengupta, Co-Founder & Director

    Dr. Shiladitya Sengupta is an assistant professor of medicine at Harvard Medical School. He is also the Co-Founder of Invictus Oncology, Cerulean Pharmaceuticals and Mitra Biotech. Shiladitya's research focuses on the development of novel nanomedicines for cancer and angiogenesis-based diseases. In 2005, he was recognized as one of the top 35 innovators worldwide by MIT Technology Review magazine. He has also received the Shakuntala Amir Chand Award from the Indian Council for Medical Research.

    Shiladitya is an alumnus of the All India Institute of Medical Sciences, and completed his PhD as a Nehru Scholar from Trinity College at Cambridge University and was a Fellow at MIT before joining Harvard. He has published over 35 papers, including in Nature and Proceedings of the National Academy of Sciences.

     

    Chris Garabedian, Director

     
    Chris Garabedian is a Senior Advisor at the Boston Consulting Group. Previously, Chris served as the President and Chief Executive Officer of Sarepta Therapeutics from January 2011-March 2015 and as a member of Sarepta's board of directors from June 2010-March 2015.  He is currently involved in the formation and co-founding of several early-stage biopharma companies.
     
    Chris served as Vice President of Corporate Strategy for Celgene from 2007 to December 2010 where he was responsible for strategic planning, M&A, portfolio review and other strategic initiatives.  Prior to Celgene, Chris worked at Gilead Sciences, Inc., from 1997 to 2005 where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. While at Gilead Sciences, Chris's responsibilities ranged from managing corporate development initiatives, including portfolio review and strategic planning, M&A/business development, and leading four global product launches. Chris also held various commercial development positions at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997.  He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994.
     
    Chris is a frequent speaker across a variety of topics at industry conferences.  He also serves as a Senior Advisor to the Boston Consulting Group, as a member of the MassBio Board of Directors, as a member of faculty of the GLG Institute, and as a member of the Board of Advisors for the Keck Graduate Institute.
     

    Dr. Bhaskar Chaudhuri, Non-Executive Director

    Dr. Bhaskar Chaudhuri currently works with Frazier Healthcare as an Operating Partner. Previously, Dr. Chaudhuri served as the President of Valeant Pharmaceuticals International through the end of 2010. He joined Valeant through the Company’s acquisition of Dow Pharmaceutical Sciences, Inc. in late 2008, where Dr. Chaudhuri served as President and Chief Executive Officer. Dr. Chaudhuri serves on the board of Silvergate Pharmaceuticals.

    Before joining Dow, Dr. Chaudhuri worked at Mylan Pharmaceuticals in different capacities including Executive Vice President of Scientific Affairs (Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories) and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri joined Mylan through the acquisition of Penederm Inc., where he was the Vice President of Research and Development.

    Dr. Chaudhuri has over 20 years of experience in pharmaceutical management and currently also serves on the Board of two companies. He holds a Doctorate in Physical Pharmacy, a Master of Science in Industrial Pharmacy and a Bachelor’s of Science in Pharmacy.

     

    Ranjana Kumar, Director

    A career banker with 40 years’ experience in domestic and international banking, Mrs. Ranjana Kumar has been chairman of Indian Bank, Canara Bank and National Bank for Agriculture and Rural Development (NABARD). Most recently, she served as India's Chief Vigilance Commissioner in the Central Vigilance Commission.

    Mrs. Kumar was instrumental in transforming the Indian Bank from a loss-making entity to a viable business, and was named 'India's Turnaround Queen' by The Economist for this achievement. Prior to Indian Bank, she was chairman of Canara Bank, and also served as CEO of Bank of India's US operations from 1995-99.

    In 2002, Business Standard named Mrs. Kumar 'Banker of the Year', and in 2013, she received the Lifetime Achievement Award from Business World magazine.

     

    Dr. Kumar Shiralagi, Director

    Kumar Shiralagi has a 10-plus year track record of managing high-performing investments and exits. He is a managing director at Kalaari Capital, where he serves on ten company boards and has been involved with more than 25 companies - advising investments, serving on boards, and managing exits. From 2003 to 2007, he was Country Director of Intel Capital India. He is a Senior Member of IEEE and a Charter Member of TiE. He has published more than 60 technical papers, holds 23 U.S. patents, and co-founded Lytek Corporation, a semiconductor laser manufacturer.

    Kumar graduated with an engineering degree from NIT Karnataka and a PhD in electrical engineering from Arizona State University. He also holds an MBA from the Thunderbird School of Global Management.

     

    Rajiv Maliwal, Director

    Rajiv Maliwal, 54, is the Founder and Managing Partner of Sabre Partners, a private equity firm which manages over half a billion dollars focusing on financial services, healthcare and infrastructure. He is best known for having pioneered and successfully implemented a unique private sector solution for ailing and stressed financial institutions in India (e.g. Centurion Bank, Lord Krishna Bank etc.), and more recently, in spearheading growth of healthcare in India through some innovative financing structures.

    Prior to founding Sabre Partners in 2002, Rajiv was at Standard Chartered PLC as Global Head of Private Equity. He raised a $300m fund, built a global team and invested internationally with a focus on financial services and technology. Between 1993 and 1998, he was with Goldman Sachs, Hong Kong and JP Morgan, Singapore and was responsible for setting up and growing the investment banking and securities businesses for them in South East Asia and India. He established a JV for both these firms in India with domestic partners (Goldman Sachs/Kotak Mahindra JV and JP Morgan/ICICI JV), led many M&A, Equity and Debt underwritings and originated several private equity investments. Prior to 1993, Rajiv was with Citibank, where he was responsible for corporate and investment banking in Western India.

    Rajiv graduated with an MBA from Indian Institute of Management, Bangalore in 1985 and holds a Bachelor of Engineering (Hons) degree in Mechanical Engineering from BITS, Pilani. He was awarded the IIM Bangalore, Distinguished Alumni Award in 2012. He sits on the board of several companies in India and globally. He is a member of the Board of Governors of IIM, Bangalore and was a member of Stanford Parents Advisory Board for 4 years. He is a frequent speaker at a number of educational institutions and forums internationally on entrepreneurship and regularly mentors start-ups. He is also closely associated with two not-for-profit healthcare initiatives in India in the fields of mental health and eye-care.

     

    Dr. Ranjan Pai, Director

    Dr. Ranjan Pai is the CEO of Manipal Education and Medical Group (MEMG) since 2005, the corporate holding entity of the group that focuses on Education, Healthcare and Research.

    With a keen understanding of the global business environment & a vision to place the Manipal Group on the global forefront in the space of education & healthcare, Dr. Ranjan Pai has been instrumental in restructuring the family run group & corporatizing it. Taking forward the Group’s 60 year legacy, he has spearheaded & scaled the various business entities of the group to impressive heights both in India & abroad.

    He incubated Manipal Global Education Services, a leading global education and education services company headquartered in Bangalore, India. The company addresses the entire learning life cycle, covering both on-campus and campus-independent graduate and post-graduate studies, vocational skill development, corporate training and systemic services. Ranjan conceptualized the transformation of Manipal Hospitals into a leading for-profit multi-specialty healthcare chain in India. He set up Stempeutics to undertake cutting-edge research in stem cell therapies. He also founded Manipal Infrastructure Services with the vision of creating India’s premier student accommodation and facilities Services Company. These companies are run by professional management teams. Ranjan has a proven track record of successfully raising funding at different stages for MEMG Group Companies from marquee strategic and financial investors, and delivering above market returns to his investors. Ranjan has incubated or has been an active financial investor in several start-ups. His investment track record includes several exceptional exits. He co-founded Aarin Capital to realize his ambition to actively engage with new ideas and dynamic entrepreneurs in life sciences, health care and training/skill augmentation.

    A medical doctor by qualification, Ranjan graduated from Manipal University, Manipal and proceeded to study Hospital Administration in the United States.

     

    Alan Rosling, Director

    Alan Rosling founded Griffin Growth Partners, a consulting business focused on assisting international companies with Asian strategy.  He has advised a large number of 

    international clients on growth strategies for the region as well as Indian companies on internationalisation.  Alan also is co-founder and a Director of Kiran Energy, one of India’s leading independent solar power producers.  

    He is a Non Executive Director of Coats Plc and LNGaz, a Canadian small-scale LNG company which he co-founded.  LNGaz has entered a Joint Venture with Stolt-Nielsen to develop an LNG facility in Quebec.   He is also Senior Advisor to Navam Capital, an early stage technology venture fund.

    Alan was an Executive Director of Tata Sons Limited for five years from 2004 and was the Director responsible for internationalising the Tata Group. From 1998 to 2003 he was Chairman of the Jardine Matheson Group in India.  His earlier career included the Policy Unit at No.10 Downing Street; Strategy Director at United Distillers, CEO of a division of Courtaulds Textiles and S.G. Warburg.

    Alan was educated at Cambridge University and the Harvard Business School.
     

    Dr. Rajesh Gokhale, Co-Founder & Director

    Dr. Rajesh is the Ex-Director at the Institute of Genomics and Integrative Biology in New Delhi, Dr. Rajesh Gokhale received his PhD in 1996 from the Indian Institute of Science, Bangalore and worked as a postdoctoral fellow at Stanford University. In 2006, he was awarded the Shanti Swaroop Bhatnagar Prize in Biological Sciences.

    Rajesh is investigating how molecular repertoire in nature is generated from a limited number of genes. He has published over 40 papers in leading journals such as Nature, Nature Chemical Biology, Proceedings of the National Academy of Sciences and Molecular Cell. He is an honorary faculty member of the Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore and a Fellow of the Indian Academy of Sciences.

    Copyright © 2015 Vyome Biosciences. All rights reserved.